Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) Enterprise Value (2016 - 2026)

Veracyte's Enterprise Value history spans 14 years, with the latest figure at -$362.6 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 51.65% to -$362.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$362.6 million, a 51.65% decrease, with the full-year FY2025 number at -$362.6 million, down 51.65% from a year prior.
  • Enterprise Value hit -$362.6 million in Q4 2025 for Veracyte, down from -$315.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for VCYT hit a ceiling of -$153.4 million in Q2 2022 and a floor of -$362.6 million in Q4 2025.
  • Historically, Enterprise Value has averaged -$223.0 million across 5 years, with a median of -$205.8 million in 2023.
  • Biggest five-year swings in Enterprise Value: crashed 122.14% in 2021 and later surged 53.15% in 2022.
  • Tracing VCYT's Enterprise Value over 5 years: stood at -$173.2 million in 2021, then grew by 10.94% to -$154.2 million in 2022, then plummeted by 40.33% to -$216.5 million in 2023, then dropped by 10.46% to -$239.1 million in 2024, then tumbled by 51.65% to -$362.6 million in 2025.
  • Business Quant data shows Enterprise Value for VCYT at -$362.6 million in Q4 2025, -$315.6 million in Q3 2025, and -$219.5 million in Q2 2025.